Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$8.52 ▲ +0.15
(+1.79%)
MKT CAP: $2.18B • VOL: 4.52M
52W L $6 52W H $11
ROARABLE / RQD
B+ • 78/100
PIOTROSKI
6 / 9
BCRX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $341.0M | -$2.5M | -$103.7M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | $263.9M | -$88.9M | -$226.5M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $347.4M | -$52.0M | -$95.1M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $347.4M | -$52.0M | -$95.1M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | 95.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $89.7M | $104.7M | — |
| Total Debt (Short + Long Term) | $0 | $314.9M | — |
| Total Stockholders' Equity | -$119.2M | -$475.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BCRX.